COLUMBIA, Md., Aug. 6, 2025 /PRNewswire/ -- Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, today announced a major expansion of its Study ...
New integrations with industry leaders in EDC, eConsent, IRT/RTSM, eCOA, payments, and patient engagement expands Advarra's connected ecosystem, giving sponsors, CROs, and research sites secure, ...
Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ("Trodelvy") Gilead's Trop-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results